お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:患者由来異種移植 (PDX) モデルの世界市場 (~2026年):タイプ (マウス・ラット)・腫瘍区分 (胃腸・婦人科・血液)・用途 (前臨床医薬品開発・バイオマーカー分析)・エンドユーザー (製薬・バイオテクノロジー・CRO)・地域別
市場調査レポート
商品コード
1001813

患者由来異種移植 (PDX) モデルの世界市場 (~2026年):タイプ (マウス・ラット)・腫瘍区分 (胃腸・婦人科・血液)・用途 (前臨床医薬品開発・バイオマーカー分析)・エンドユーザー (製薬・バイオテクノロジー・CRO)・地域別

Patient-Derived Xenograft/PDX Model Market by Type (Mouse, Rat), Tumor Type (Gastrointestinal, Gynecological, Hematological), Application (Preclinical Drug Development, Biomarker analysis), End User (Pharma, Biotech, CROs) - Global Forecast to 2026

出版日: | 発行: MarketsandMarkets | ページ情報: 英文 171 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=110.22円
患者由来異種移植 (PDX) モデルの世界市場 (~2026年):タイプ (マウス・ラット)・腫瘍区分 (胃腸・婦人科・血液)・用途 (前臨床医薬品開発・バイオマーカー分析)・エンドユーザー (製薬・バイオテクノロジー・CRO)・地域別
出版日: 2021年04月19日
発行: MarketsandMarkets
ページ情報: 英文 171 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

世界の患者由来異種移植 (PDX) モデルの市場規模は予測期間中16.4%のCAGRで推移し、2021年の1億4000万米ドルから、2026年には2億9900万米ドルの規模に成長すると予測されています。

個別化医療への需要の高まり、癌研究への継続的な支援、製薬会社によるR&Dの拡大などの要因が同市場の成長を推進しています。また、ヒト化PDXモデルへの需要の高まりがさらなる成長の機会を示すと期待されています。一方で、個別化PDXモデルの高コスト性、癌研究における動物実験の倫理性に関する厳格なガイドライン、PDXモデルに付随する各種制約などが予測期間中の市場成長を一定程度抑制すると予測されています。

当レポートでは、世界の患者由来異種移植 (PDX) モデルの市場を調査し、市場の定義と概要、バリューチェーン、新型コロナウイルス感染症 (COVID-19) およびその他の市場影響因子の分析、法規制環境、技術・特許の動向、市場規模の推移・予測、タイプ・腫瘍区分・用途・エンドユーザー・地域/主要国別の内訳、競合環境、主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 重要考察

第5章 市場概要

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
    • 課題
  • COVID-19の影響
  • 技術分析
  • 価格分析
  • バリューチェーン分析
  • PDXエコシステム分析
  • ポーターのファイブフォース分析
  • 規制分析
  • 特許分析

第6章 市場分析・予測:タイプ別

  • マウスモデル
  • ラットモデル

第7章 市場分析・予測:腫瘍区分別

  • 消化管腫瘍モデル
  • 婦人科腫瘍モデル
  • 呼吸器腫瘍モデル
  • 泌尿器腫瘍モデル
  • 血液腫瘍モデル
  • その他

第8章 市場分析・予測:用途別

  • 前臨床医薬品開発
  • バイオマーカー分析
  • 癌の基礎調査

第9章 市場分析・予測:エンドユーザー別

  • 製薬・バイオテクノロジー企業
  • CRO
  • 学術研究機関

第10章 市場分析・予測:地域・主要国別

  • 北米
    • 米国
    • カナダ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • その他
  • アジア太平洋
    • 中国
    • 日本
    • その他
  • ラテンアメリカ
  • 中東・アフリカ

第11章 競合情勢

  • 概要
  • 市場評価の枠組み
  • 市場シェア分析
  • トップ企業の収益シェア分析
  • 企業評価クアドラント
  • 企業評価クアドラント:新興企業/中小企業
  • 企業の製品フットプリント
  • 企業の地理的フットプリント
  • 競合シナリオ

第12章 企業プロファイル

  • 主要企業
    • JSR CORPORATION
    • WUXI APPTEC
    • THE JACKSON LABORATORY
    • CHARLES RIVER LABORATORIES
    • CHAMPIONS ONCOLOGY
    • ONCODESIGN
    • ENVIGO
    • PHARMATEST SERVICES
    • HERA BIOLABS
    • EPO BERLIN-BUCH GMBH
    • XENTECH
    • UROSPHERE
  • その他の企業
    • ABNOVA CORPORATION
    • GENESIS BIOTECHNOLOGY GROUP
    • EXPLORA BIOLABS
    • BIOCYTOGEN
    • LIVING TUMOR LABORATORY
    • BIODURO
    • ARAGEN LIFE SCIENCES W.E.F
    • SHANGHAI LIDE BIOTECH

第13章 付録

目次
Product Code: BT 5576

The global Patient-Derived Xenograft/PDX models market size is projected to reach USD 299 million by 2026 from USD 140 million in 2021, at a CAGR of 16.4% during the forecast period. Market growth is driven mainly by factors such as growing demand for personalized medicine, continuous support for cancer research, and growth in pharma R&D. Rising demand for humanized PDX models is expected to provide growth opportunity for players in the PDX models market. However, the high cost of personalized PDX models, stringent guidelines regarding the ethical use of animals in cancer research, and limitations associated with PDX models are expected to restrain the growth of this market to a certain extent during the forecast period.

"The preclinical drug development segment accounted for the highest growth rate in the PDX models market, by application, during the forecast period"

The PDX models market is segmented into preclinical drug development, biomarker analysis, and basic cancer research. The preclinical drug development segment accounted for the highest growth rate in the PDX models market during the forecast period. This segment's high growth rate can be attributed to the rising number of clinical trials every year.

"Contract research organizations segment accounted for the highest CAGR"

Based on end users, the PDX models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. During the forecast period contract research organizations accounted for the highest growth rate. The high growth rate in this segment can be attributed to the increasing number of pharmaceutical companies outsourcing their preclinical studies to CROs.

"Rat models segment accounted for the highest CAGR"

Based on type, the PDX models market is segmented into mice models and rat models. The rat models segment accounted for the highest growth rate during the forecast period. Growth in this market is mainly driven by the larger size of rats, which enhances surgical manipulation. Moreover, the development of immunodeficient rats will further drive the usage of rat models in PDX model generation.

"Respiratory tumor models segment accounted for the highest CAGR"

Based on tumor type, the PDX models market is segmented into gastrointestinal tumor models, gynecological tumor models, respiratory tumor models, urological tumor models, hematological tumor models, and other tumor models. The respiratory tumor models segment accounted for the highest growth rate during the forecast period. The key factor driving this segment's growth is the increasing incidence of lung cancers globally.

"Asia Pacific: The fastest-growing country in the PDX models market"

The PDX models market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East and Africa. Asia Pacific is projected to register the highest CAGR during the forecast period. Factors such as the rising R&D spending, growing public-private partnerships, and increasing government funding are factors driving the growth of the PDX models market in this region.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply Side- 70%, and Demand Side - 30%
  • By Designation (Supply Side): Managers - 45%, CXOs and Directors - 30%, and Executives- 25%
  • By Region: North America -40%, Europe -25%, Asia-Pacific -20%, Latin America -10%, and Middle East and Africa -5%

Lists of Companies Profiled in the Report:

  • JSR Corporation (Japan)
  • WuXi AppTec (China)
  • Champions Oncology, Inc. (US)
  • THE JACKSON LABORATORY (US)
  • Charles River Laboratories (US)
  • Oncodesign (France)
  • Envigo (US)
  • Pharmatest Services (Finland)
  • Hera BioLabs (US)
  • EPO Berlin-Buch GmbH (Germany)
  • Xentech (France)
  • Urosphere (France)
  • Abnova Corporation (Taiwan)
  • Genesis Biotechnology Group (US)
  • Explora BioLabs (US)
  • Biocytogen (US)
  • Living Tumor Laboratory (Canada)
  • Bioduro (US)
  • Aragen Life Sciences w.e.f, (US)
  • Shanghai Lide Biotech Co., Ltd. (China)

Research Coverage:

This report provides a detailed picture of the PDX models market. It aims at estimating the size and future growth potential of the market across different segments, such as type, tumor type, application, end user, and region. The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall PDX models market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 OBJECTIVES OF THE STUDY
  • 1.2 MARKET DEFINITION
    • 1.2.1 INCLUSIONS & EXCLUSIONS
  • 1.3 MARKET SCOPE
    • 1.3.1 MARKETS COVERED
    • 1.3.2 YEARS CONSIDERED IN THE REPORT
  • 1.4 CURRENCY
  • 1.5 LIMITATIONS
  • 1.6 STAKEHOLDERS
  • 1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • FIGURE 1 RESEARCH DESIGN
    • 2.1.1 SECONDARY DATA
    • 2.1.2 PRIMARY DATA
    • FIGURE 2 PRIMARY SOURCES
    • FIGURE 3 PDX MODELS MARKET: BREAKDOWN OF PRIMARIES
      • 2.1.2.1 Key industry insights
  • 2.2 MARKET SIZE ESTIMATION
    • FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 - REVENUE SHARE ANALYSIS, 2020
    • FIGURE 5 AVERAGE MARKET SIZE ESTIMATION, 2020
    • FIGURE 6 PDX MODELS MARKET: CAGR PROJECTIONS, 2021-2026
    • FIGURE 7 PDX MODELS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
    • FIGURE 8 DATA TRIANGULATION METHODOLOGY
  • 2.4 RESEARCH ASSUMPTIONS
  • 2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY

    • FIGURE 9 PDX MODELS MARKET, BY TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 10 PDX MODELS MARKET, BY TUMOR TYPE, 2021 VS. 2026 (USD MILLION)
    • FIGURE 11 PDX MODELS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    • FIGURE 12 PDX MODELS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    • FIGURE 13 PDX MODELS MARKET: GEOGRAPHIC SNAPSHOT

4 PREMIUM INSIGHTS

  • 4.1 PDX MODELS MARKET OVERVIEW
    • FIGURE 14 INCREASING SUPPORT FOR CANCER RESEARCH FROM PUBLIC AND PRIVATE SECTORS AND GROWING DEMAND FOR PRECISION MEDICINE ARE KEY GROWTH DRIVERS
  • 4.2 NORTH AMERICA: PDX MODELS MARKET, MARKET SHARE (2020)
    • FIGURE 15 MICE MODELS COMMANDED THE LARGEST SHARE OF THE NORTH AMERICAN PDX MODELS MARKET IN 2020
  • 4.3 PDX MODELS MARKET SHARE, BY END USER (2020)
    • FIGURE 16 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES COMMANDED THE LARGEST SHARE OF THE PDX MODELS MARKET IN 2020
  • 4.4 PDX MODELS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
    • FIGURE 17 CHINA TO WITNESS THE HIGHEST GROWTH IN THE PDX MODELS MARKET DURING THE FORECAST PERIOD

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • FIGURE 18 PDX MODELS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    • TABLE 1 PDX MODELS MARKET: IMPACT ANALYSIS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Growing demand for personalized medicine
      • 5.2.1.2 Continuous support for cancer research from the public & private sectors
      • 5.2.1.3 Rising pharma R&D
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 High cost of personalized PDX models
      • 5.2.2.2 Stringent guidelines for the use of animal models in cancer research
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Rising demand for humanized PDX models
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Limitations of PDX models
  • 5.3 IMPACT OF THE COVID-19 OUTBREAK ON THE GROWTH OF THE PDX MODELS MARKET
  • 5.4 TECHNOLOGICAL ANALYSIS
  • 5.5 PRICING ANALYSIS
  • 5.6 VALUE CHAIN ANALYSIS
    • FIGURE 19 VALUE CHAIN ANALYSIS OF PDX MODELS MARKET: R&D AND MANUFACTURING PHASES ADD MAXIMUM VALUE
    • FIGURE 20 VALUE CHAIN: CREATION OF PDX MODELS-MAXIMUM VALUE IS ADDED DURING THE IMPLANTATIONS OF TUMOR CELLS IN IMMUNODEFICIENT MICE OR RATS
  • 5.7 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET
    • FIGURE 21 ECOSYSTEM ANALYSIS OF THE PDX MODELS MARKET
    • TABLE 2 SUPPLY CHAIN ECOSYSTEM
  • 5.8 PORTER'S FIVE FORCES ANALYSIS
    • TABLE 3 PDX MODELS MARKET: PORTER'S FIVE FORCES ANALYSIS
    • 5.8.1 THREAT OF NEW ENTRANTS
    • 5.8.2 THREAT OF SUBSTITUTES
    • 5.8.3 BARGAINING POWER OF BUYERS
    • 5.8.4 BARGAINING POWER OF SUPPLIERS
    • 5.8.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.9 REGULATORY ANALYSIS
    • 5.9.1 NORTH AMERICA
    • 5.9.2 EUROPE
    • 5.9.3 ASIA PACIFIC
      • 5.9.3.1 China
      • 5.9.3.2 Japan
      • 5.9.3.3 India
      • 5.9.3.4 Australia
    • 5.9.4 LATIN AMERICA
    • 5.9.5 MIDDLE EAST & AFRICA
  • 5.10 PATENT ANALYSIS
    • FIGURE 22 PATENTS GRANTED FOR PDX MODELS, JANUARY 2010-DECEMBER 2020

6 PDX MODELS MARKET, BY TYPE

  • 6.1 INTRODUCTION
    • TABLE 4 PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
  • 6.2 MICE MODELS
    • 6.2.1 EASE OF PROCUREMENT AND WIDE AVAILABILITY OF MICE MODELS DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 5 PDX MICE MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 6 NORTH AMERICA: PDX MICE MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 7 EUROPE: PDX MICE MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 8 ASIA PACIFIC: PDX MICE MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 6.3 RAT MODELS
    • 6.3.1 FACTORS SUCH AS EASIER SURGICAL MANIPULATION AND LARGER TUMOR SIZE WILL SUPPORT USE OF RAT MODELS
    • TABLE 9 PDX RAT MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 10 NORTH AMERICA: PDX RAT MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 11 EUROPE: PDX RAT MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 12 ASIA PACIFIC: PDX RAT MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

7 PDX MODELS MARKET, BY TUMOR TYPE

  • 7.1 INTRODUCTION
    • TABLE 13 PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
  • 7.2 GASTROINTESTINAL TUMOR MODELS
    • 7.2.1 NEWLY DEVELOPED GASTROINTESTINAL TUMOR MODELS MIMIC THE TUMOR BETTER THAN PREVIOUS MODELS
    • TABLE 14 GASTROINTESTINAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 15 NORTH AMERICA: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 16 EUROPE: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 17 ASIA PACIFIC: GASTROINTESTINAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.3 GYNECOLOGICAL TUMOR MODELS
    • 7.3.1 HIGH INCIDENCE OF TARGET CANCERS HAS DRIVEN DEMAND FOR TUMOR MODELS
    • TABLE 18 GYNECOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 19 NORTH AMERICA: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 20 EUROPE: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 21 ASIA PACIFIC: GYNECOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.4 RESPIRATORY TUMOR MODELS
    • 7.4.1 RISING PREVALENCE OF LUNG CANCER TO DRIVE MARKET GROWTH
    • TABLE 22 RESPIRATORY TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 23 NORTH AMERICA: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 24 EUROPE: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 25 ASIA PACIFIC: RESPIRATORY TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.5 UROLOGICAL TUMOR MODELS
    • 7.5.1 COMPANIES ARE FOCUSING ON EXPANDING THEIR PORTFOLIO FOR UROLOGICAL CANCERS
    • TABLE 26 UROLOGICAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 27 NORTH AMERICA: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 28 EUROPE: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 29 ASIA PACIFIC: UROLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.6 HEMATOLOGICAL TUMOR MODELS
    • 7.6.1 NEW STRAINS SUCH AS NSG AND NOG HAVE INCREASED THE LIFE SPAN OF HEMATOLOGICAL TUMOR MODELS
    • TABLE 30 HEMATOLOGICAL TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 31 NORTH AMERICA: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 32 EUROPE: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 33 ASIA PACIFIC: HEMATOLOGICAL TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
  • 7.7 OTHER TUMOR MODELS
    • TABLE 34 OTHER TUMOR MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 35 NORTH AMERICA: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 36 EUROPE: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 37 ASIA PACIFIC: OTHER TUMOR MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)

8 PDX MODELS MARKET, BY APPLICATION

  • 8.1 INTRODUCTION
    • TABLE 38 PDX MODELS MARKET, BY APPLICATION, 2021-2026 (USD MILLION)
  • 8.2 PRECLINICAL DRUG DEVELOPMENT
    • 8.2.1 RISE IN NUMBER OF CLINICAL TRIALS WILL DRIVE THE GROWTH OF THIS SEGMENT
    • TABLE 39 PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 40 NORTH AMERICA: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 41 EUROPE: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 42 ASIA PACIFIC: PDX MODELS MARKET FOR PRECLINICAL DRUG DEVELOPMENT, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.3 BIOMARKER ANALYSIS
    • 8.3.1 GROWING INTEREST IN PRECISION MEDICINE WILL CONTRIBUTE TO THE DEMAND FOR PDX MODELS FOR BIOMARKER ANALYSIS
    • TABLE 43 PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 44 NORTH AMERICA: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 45 EUROPE: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 46 ASIA PACIFIC: PDX MODELS MARKET FOR BIOMARKER ANALYSIS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 8.4 BASIC CANCER RESEARCH
    • 8.4.1 RISING FUNDING FOR CANCER RESEARCH WILL DRIVE MARKET GROWTH IN THIS SEGMENT
    • TABLE 47 PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 48 NORTH AMERICA: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 49 EUROPE: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 50 ASIA PACIFIC: PDX MODELS MARKET FOR BASIC CANCER RESEARCH, BY COUNTRY, 2019-2026 (USD MILLION)

9 PDX MODELS MARKET, BY END USER

  • 9.1 INTRODUCTION
    • TABLE 51 PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
    • 9.2.1 RISING COLLABORATION BETWEEN PHARMA & BIOTECH COMPANIES FOR DEVELOPING CANCER THERAPEUTICS
    • TABLE 52 PDX MODELS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 53 NORTH AMERICA: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 54 EUROPE: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 55 ASIA PACIFIC: PDX MODELS MARKET FOR PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.3 CONTRACT RESEARCH ORGANIZATIONS
    • 9.3.1 RISING OUTSOURCING OF DRUG DISCOVERY SERVICES WILL DRIVE MARKET GROWTH
    • TABLE 56 PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 57 NORTH AMERICA: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 58 EUROPE: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 59 ASIA PACIFIC: PDX MODELS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019-2026 (USD MILLION)
  • 9.4 ACADEMIC & RESEARCH INSTITUTIONS
    • 9.4.1 INCREASE IN GOVERNMENT LIFE SCIENCES R&D EXPENDITURE WILL CONTRIBUTE TO THE GROWTH OF THIS SEGMENT
    • TABLE 60 PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2019-2026 (USD MILLION)
    • TABLE 61 NORTH AMERICA: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 62 EUROPE: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 63 ASIA PACIFIC: PDX MODELS MARKET FOR ACADEMIC & RESEARCH INSTITUTIONS, BY COUNTRY, 2019-2026 (USD MILLION)

10 PDX MODELS MARKET, BY REGION

  • 10.1 INTRODUCTION
    • TABLE 64 PDX MODELS MARKET, BY REGION, 2019-2026 (USD MILLION)
  • 10.2 NORTH AMERICA
    • FIGURE 23 NORTH AMERICA: PDX MODELS MARKET SNAPSHOT
    • TABLE 65 NORTH AMERICA: PDX MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 66 NORTH AMERICA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 67 NORTH AMERICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 68 NORTH AMERICA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 69 NORTH AMERICA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.1 US
      • 10.2.1.1 Growing focus on cancer research in the US will drive market growth
    • TABLE 70 US: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 71 US: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 72 US: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 73 US: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.2.2 CANADA
      • 10.2.2.1 Growth in Canada can be attributed to rising funding for stem cell research in the country
    • TABLE 74 CANADA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 75 CANADA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 76 CANADA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 77 CANADA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.3 EUROPE
    • TABLE 78 EUROPE: PDX MODELS MARKET, BY COUNTRY/REGION, 2019-2026 (USD MILLION)
    • TABLE 79 EUROPE: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 80 EUROPE: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 81 EUROPE: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 82 EUROPE: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.1 GERMANY
      • 10.3.1.1 Government funding for life science R&D and basic cancer research will drive market growth
    • TABLE 83 GERMANY: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 84 GERMANY: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 85 GERMANY: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 86 GERMANY: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.2 UK
      • 10.3.2.1 The rising incidence of cancer cases will lead to an increase in cancer research, which will drive market growth
    • TABLE 87 UK: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 88 UK: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 89 UK: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 90 UK: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.3 FRANCE
      • 10.3.3.1 Increasing government funding for cancer research
    • TABLE 91 FRANCE: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 92 FRANCE: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 93 FRANCE: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 94 FRANCE: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.3.4 ROE
    • TABLE 95 ROE: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 96 ROE: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 97 ROE: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 98 ROE: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.4 ASIA PACIFIC
    • FIGURE 24 ASIA PACIFIC: PDX MODELS MARKET SNAPSHOT
    • TABLE 99 ASIA PACIFIC: PDX MODELS MARKET, BY COUNTRY, 2019-2026 (USD MILLION)
    • TABLE 100 ASIA PACIFIC: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 101 ASIA PACIFIC: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 102 ASIA PACIFIC: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 103 ASIA PACIFIC: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.1 CHINA
      • 10.4.1.1 The growing pharmaceutical industry and rising number of CROs in the country will drive market growth
    • TABLE 104 CHINA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 105 CHINA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 106 CHINA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 107 CHINA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.2 JAPAN
      • 10.4.2.1 Research collaborations and growing geriatric population-key growth drivers in Japan
    • TABLE 108 JAPAN: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 109 JAPAN: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 110 JAPAN: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 111 JAPAN: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
    • 10.4.3 REST OF ASIA PACIFIC
    • TABLE 112 ROAPAC: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 113 ROAPAC: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 114 ROAPAC: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 115 ROAPAC: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.5 LATIN AMERICA
    • 10.5.1 RISING PHARMACEUTICAL R&D EXPENDITURE IN THE REGION WILL DRIVE THE GROWTH OF THE MARKET
    • TABLE 116 LATIN AMERICA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 117 LATIN AMERICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 118 LATIN AMERICA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 119 LATIN AMERICA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)
  • 10.6 MIDDLE EAST & AFRICA
    • 10.6.1 MARKET GROWTH DRIVEN BY CHANGING DEMOGRAPHICS AND FAVORABLE POLICIES FOR PHARMA R&D
    • TABLE 120 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TYPE, 2019-2026 (USD MILLION)
    • TABLE 121 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY TUMOR TYPE, 2019-2026 (USD MILLION)
    • TABLE 122 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY APPLICATION, 2019-2026 (USD MILLION)
    • TABLE 123 MIDDLE EAST AND AFRICA: PDX MODELS MARKET, BY END USER, 2019-2026 (USD MILLION)

11 COMPETITIVE LANDSCAPE

  • 11.1 OVERVIEW
  • 11.2 MARKET EVALUATION FRAMEWORK
    • TABLE 124 MARKET EVALUATION FRAMEWORK: PARTNERSHIPS, AGREEMENTS, JOINT VENTURES, AND COLLABORATIONS-THE MAJOR STRATEGIES ADOPTED BY PLAYERS
  • 11.3 MARKET SHARE ANALYSIS
    • FIGURE 25 PDX MODELS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2020
  • 11.4 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS
    • FIGURE 26 TOP MARKET PLAYERS DOMINATE THE PDX MODELS MARKET
  • 11.5 COMPANY EVALUATION QUADRANT
    • 11.5.1 STARS
    • 11.5.2 EMERGING LEADERS
    • 11.5.3 PERVASIVE
    • 11.5.4 EMERGING COMPANIES
    • FIGURE 27 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT, 2020
  • 11.6 COMPANY EVALUATION QUADRANT: START-UPS/SMES
    • 11.6.1 PROGRESSIVE COMPANIES
    • 11.6.2 STARTING BLOCKS
    • 11.6.3 RESPONSIVE COMPANIES
    • 11.6.4 DYNAMIC COMPANIES
    • FIGURE 28 PDX MODELS MARKET: COMPANY EVALUATION QUADRANT FOR START-UPS/SMES, 2020
  • 11.7 COMPANY PRODUCT FOOTPRINT
    • TABLE 125 PRODUCT PORTFOLIO ANALYSIS: PDX MODELS MARKET (2020)
  • 11.8 COMPANY GEOGRAPHIC FOOTPRINT
    • TABLE 126 GEOGRAPHIC REVENUE MIX: PDX MODELS MARKET (2020)
  • 11.9 COMPETITIVE SCENARIO
    • 11.9.1 PDX MODELS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2018-FEBRUARY 2021
    • 11.9.2 PDX MODELS MARKET: DEALS, JANUARY 2019-FEBRUARY 2021
    • 11.9.3 PDX MODELS MARKET: OTHER DEVELOPMENTS, JANUARY 2018-FEBRUARY 2021

12 COMPANY PROFILES

  • (Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)**
  • 12.1 KEY MARKET PLAYERS
    • 12.1.1 JSR CORPORATION
    • FIGURE 29 JSR CORPORATION: COMPANY SNAPSHOT (2019)
    • 12.1.2 WUXI APPTEC
    • FIGURE 30 WUXI APPTEC: COMPANY SNAPSHOT (2020)
    • 12.1.3 THE JACKSON LABORATORY
    • FIGURE 31 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019)
    • 12.1.4 CHARLES RIVER LABORATORIES
    • FIGURE 32 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2020)
    • 12.1.5 CHAMPIONS ONCOLOGY
    • FIGURE 33 CHAMPIONS ONCOLOGY: COMPANY SNAPSHOT (2020)
    • 12.1.6 ONCODESIGN
    • FIGURE 34 ONCODESIGN: COMPANY SNAPSHOT (2020)
    • 12.1.7 ENVIGO
    • 12.1.8 PHARMATEST SERVICES
    • 12.1.9 HERA BIOLABS
    • 12.1.10 EPO BERLIN-BUCH GMBH
    • 12.1.11 XENTECH
    • 12.1.12 UROSPHERE
  • 12.2 OTHER PLAYERS
    • 12.2.1 ABNOVA CORPORATION
    • 12.2.2 GENESIS BIOTECHNOLOGY GROUP
    • 12.2.3 EXPLORA BIOLABS
    • 12.2.4 BIOCYTOGEN
    • 12.2.5 LIVING TUMOR LABORATORY
    • 12.2.6 BIODURO
    • 12.2.7 ARAGEN LIFE SCIENCES W.E.F
    • 12.2.8 SHANGHAI LIDE BIOTECH
  • *Details on Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

13 APPENDIX

  • 13.1 DISCUSSION GUIDE
  • 13.2 KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.3 AVAILABLE CUSTOMIZATIONS
  • 13.4 RELATED REPORTS
  • 13.5 AUTHOR DETAILS
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.